Amgen Stock Deemed Fairly Valued Amid Positive Trial Results
Amgen Inc (NASDAQ: AMGN) announced encouraging Phase 3 trial results for its bispecific T-cell engager Imdelltra combined with AstraZeneca's PD-L1 inhibitor Imfinzi, targeting extensive-stage small cell lung cancer (ES-SCLC).
The combination met its primary endpoint of overall survival and achieved significant secondary endpoints, positioning Amgen for upcoming regulatory filings.
Amgen offers a dividend yield of 2.48% with a payout ratio of 44%, supported by a healthy 3-year dividend growth rate of 7.1%, indicating a sustainable and attractive income stream; the stock is currently deemed fairly valued by GuruFocus with a GF Value™ of $365.80 versus the market price of $395.73.
The company's financial health is reflected in its GF Score™, which stands at a robust 85 out of 100, driven primarily by its exceptional profitability and growth metrics, though tempered by moderate financial strength and momentum.